胃癌免疫治疗相关外周血生物标志物研究进展  

Progress of biomarkers in peripheral blood of immunotherapy for gastric cancer

作　　者：赵雯慧 王梦祥 周玟 陈妍[2] ZHAO Wenhui;WANG Mengxiang;ZHOU Min;CHEN Yan(Department of oncology,The Affiliated Cancer Hospital of Nanjing Medical University/Jiangsu Cancer Hospital/Jiangsu Cancer Prevention and Treatment Institute,Nanjing 210009,China;Department of Chinese Medicine,The Affiliated Cancer Hospital of Nanjing Medical University/Jiangsu Cancer Hospital/Jiangsu Cancer Prevention and Treatment Institute,Nanjing 210009,China)

机构地区：[1]南京医科大学附属肿瘤医院/江苏省肿瘤医院/江苏省肿瘤防治研究所肿瘤科,江苏南京210009 [2]南京医科大学附属肿瘤医院/江苏省肿瘤医院/江苏省肿瘤防治研究所中医科,江苏南京210009

出　　处：《中国肿瘤外科杂志》2025年第1期87-97,共11页Chinese Journal of Surgical Oncology

基　　金：国家自然科学基金面上项目(81874452);江苏省中医药管理局专题研究项目(ZT202211)。

摘　　要：以免疫检查点抑制剂(ICI)为代表的免疫治疗深度改变了胃癌(GC)的治疗模式,微卫星不稳定性(MSI)、EB病毒感染和肿瘤组织程序性死亡受体配体1(PD-L1)表达水平等可有效预测胃癌免疫治疗的疗效,但仍有部分患者无法从免疫治疗中获益或出现免疫相关不良反应,迫切需要探索更多的预测性生物标志物用于选择免疫受益人群。组织标本有创、难以克服肿瘤的时空异质性,而外周血标志物无创、可重复性强,同时可涵盖肿瘤和宿主两方面的信息,有助于完善患者分层治疗策略。文章从肿瘤及宿主相关生物标志物两大方面总结GC免疫检查点抑制剂治疗相关外周血生物标志物的研究进展,旨在为胃癌患者的免疫治疗选择和疗效预测提供一定的参考。Immunotherapy represented by immune checkpoint inhibitors(ICIs)has deeply changed the treatment paradigm of gastric cancer(GC).Microsatellite instability(MSI),EBV infection,and tumor tissue programmed death receptor ligand 1(PD-L1)expression levels can effectively predict the efficacy of immunotherapy for GC,but there are still some patients who do not benefit or experience immune-related adverse effects,so there is an urgent need to explore more predictive biomarkers for selecting the immunization beneficiary population.Tissue specimens are invasive and difficult to overcome the spatiotemporal heterogeneity of tumors,while peripheral blood markers are noninvasive and reproducible,and can cover both tumor and host information,which can help to improve the strategy of patient stratification.In this paper,we summarize the research progress of peripheral blood biomarkers related to GC immune checkpoint inhibitor therapy from two major aspects,namely,tumor-and host-related biomarkers,with the aim of providing certain references for the selection of immunotherapy and the prediction of therapeutic efficacy in gastric cancer patients.

关 键 词：胃癌 免疫检查点抑制剂 免疫治疗 外周血生物标志物 研究进展 

分 类 号：R735.2[医药卫生—肿瘤]